Share this article
Share this article
SUZHOU, China, Jan. 28, 2021 /PRNewswire/ Kintor Pharmaceutical Limited (HKEX: 9939) is pleased to announce that the clinical trial (the Trial ) of Proxalutamide s treatment of hospitalized COVID-19 patients was approved by the Institutional Review Board ( IRB ) of Brazil. The trial was accepted for accelerated review. We have received support from the Brazilian government in terms of medical resources allocation and expect to start with the patients recruitment over the coming weekend.
The Trial is a double-blinded, randomized and multi-center investigational study of Proxalutamide s treatment for hospitalized COVID-19 male and female patients of 18 years old or above. Approximately 588 patients (294 male and 294 female) who meet the eligibility criteria will be enrolled within 48 hours of admission to hospital. The estimated time from screening to the end of the Trial for each patient will be 28 days. The Trial will have two cohorts of
SUZHOU, China, Jan. 10, 2021 /PRNewswire/ Kintor Pharmaceutical Limited (HKEX: 9939) is pleased to update the preliminary analysis of the clinical trial of Proxalutamide for the treatment